Status | Study |
Not yet recruiting |
Study Name: Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Patients With Primary Biliary Cholangitis Condition: Primary Biliary Cholangitis Date: 2017-05-11 Interventions: Drug: APD334 APD334 active treatment for 24 weeks. O |
Recruiting |
Study Name: Swiss Primary Sclerosing Cholangitis Cohort Study Condition: Cholangitis, Sclerosing Date: 2017-05-08 |
Recruiting |
Study Name: Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid Condition: Primary Biliary Cholangitis (PBC) Date: 2017-03-28 Interventions: Drug: Elafibranor 80 mg Two co |
Recruiting |
Study Name: Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid Condition: Primary Biliary Cholangitis Date: 2017-03-24 Interventions: Drug: E6011 Intravenous admini |
Recruiting |
Study Name: Antibiotics to Decrease Post ERCP Cholangitis Condition: Cholangitis Date: 2017-03-05 Interventions: Drug: Ceftriaxone Intravenous |
RECRUITING |
Study Name: Antibiotics to Decrease Post ERCP Cholangitis Condition: Cholangitis Date: 2017-03-05 Interventions: Intravenous Ceftriaxone will be given during the procedure. |
Recruiting |
Study Name: Safety, Tolerability, and Efficacy of GS 9674 in Adults With Primary Biliary Cholangitis Without Cirrhosis Condition: Primary Biliary Cholangitis Date: 2016-06-13 Interventions: Drug: GS-9674 Tablet(s) admini |
Not yet recruiting |
Study Name: A Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis Condition: Primary Sclerosing Cholangitis Date: 2016-05-17 Interventions: Drug: hymecromone hymecromone treatment as described |
Recruiting |
Study Name: Quality of Life in Patients With Primary Sclerosing Cholangitis Condition: Primary Sclerosing Cholangitis Date: 2016-03-11 Interventions: Other: quality of life survey subjects with PSC will be administered a survey to assess their quality of |
Recruiting |
Study Name: PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis Condition: Primary Sclerosing Cholangitis Date: 2016-01-08 Interventions: Drug: Cenicriviroc 150 mg One tablet of CVC 150 mg once daily taken with food in the morning |